» Articles » PMID: 23306372

Antigenic Specificity of a Monovalent Versus Polyvalent MOMP Based Chlamydia Pecorum Vaccine in Koalas (Phascolarctos Cinereus)

Overview
Journal Vaccine
Date 2013 Jan 12
PMID 23306372
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Chlamydia continues to be a major pathogen of koalas. The bacterium is associated with ocular, respiratory and urogenital tract infections and a vaccine is considered the best option to limit the decline of mainland koala populations. Over the last 20 years, efforts to develop a chlamydial vaccine in humans have focussed on the use of the chlamydial major outer membrane protein (MOMP). Potential problems with the use of MOMP-based vaccines relate to the wide range of genetic diversity in its four variable domains. In the present study, we evaluated the immune response of koalas vaccinated with a MOMP-based C. pecorum vaccine formulated with genetically and serologically diverse MOMPs. Animals immunised with individual MOMPs developed strong antibody and lymphocyte proliferation responses to both homologous as well as heterologous MOMP proteins. Importantly, we also showed that vaccine induced antibodies which effectively neutralised various heterologous strains of koala C. pecorum in an in vitro assay. Finally, we also demonstrated that the immune responses in monovalent as well as polyvalent MOMP vaccine groups were able to recognise whole chlamydial elementary bodies, illustrating the feasibility of developing an effective MOMP based C. pecorum vaccine that could protect against a range of strains.

Citing Articles

Efficacy of a synthetic peptide Chlamydia pecorum major outer membrane protein vaccine in a wild koala (Phascolarctos cinereus) population.

Simpson S, Higgins D, Timms P, Mella V, Crowther M, Fernandez C Sci Rep. 2023; 13(1):15087.

PMID: 37699951 PMC: 10497537. DOI: 10.1038/s41598-023-42296-7.


Reduction of and Koala Retrovirus subtype B expression in wild koalas vaccinated with novel peptide and peptide/recombinant protein formulations.

Quigley B, Timms P, Nyari S, McKay P, Hanger J, Phillips S Vaccine X. 2023; 14:100329.

PMID: 37577264 PMC: 10422670. DOI: 10.1016/j.jvacx.2023.100329.


The Koala Immune Response to Chlamydial Infection and Vaccine Development-Advancing Our Immunological Understanding.

Quigley B, Timms P Animals (Basel). 2021; 11(2).

PMID: 33546104 PMC: 7913230. DOI: 10.3390/ani11020380.


A 29-year retrospective analysis of koala rescues in New South Wales, Australia.

Charalambous R, Narayan E PLoS One. 2020; 15(10):e0239182.

PMID: 33112860 PMC: 7592758. DOI: 10.1371/journal.pone.0239182.


Vaccination of koalas during antibiotic treatment for Chlamydia-induced cystitis induces an improved antibody response to Chlamydia pecorum.

Phillips S, Quigley B, Olagoke O, Booth R, Pyne M, Timms P Sci Rep. 2020; 10(1):10152.

PMID: 32576914 PMC: 7311432. DOI: 10.1038/s41598-020-67208-x.